RCM
COEPW

Radcliffe Capital Management’s Coeptis Therapeutics Warrants COEPW Stock Holding History

Radcliffe Capital Management’s Portfolio COEPW Stock Details COEPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-70,506
Closed -$5.25K – 475
2023
Q2 		$5.25K Sell
70,506
-2,694
-4% -$321 ﹤0.01% 497
2023
Q1 		$12K Buy
73,200
+35,700
+95% +$4.61K ﹤0.01% 507
2022
Q4 		$57.4K Sell
37,500
-37,400
-50% -$2.5K ﹤0.01% 869
2022
Q3 		$763K Hold
74,900
– – 0.02% 993
2022
Q2 		$755K Hold
74,900
– – 0.02% 1049
2022
Q1 		$756K Hold
74,900
– – 0.02% 1049
2021
Q4 		$749K Hold
74,900
– – 0.02% 911
2021
Q3 		$745K Hold
74,900
– – 0.02% 773
2021
Q2 		$739K Hold
74,900
– – 0.02% 794
2021
Q1 		$732K Buy
+74,900
New +$70.3K 0.03% 615

Other funds holding COEPW

CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Radcliffe Capital Management's COEPW Position: Q3 2023 in Review

Radcliffe Capital Management sold out of Coeptis Therapeutics Warrants (COEPW) in Q3 2023, closing a stake of 70,506 shares — an estimated $5.25K sold.

Radcliffe Capital Management first reported a position in COEPW in Q1 2021 and held it in 10 quarters. The position peaked at $763K in Q3 2022. 19 funds tracked by Wall St. Rank hold COEPW as of Q3 2023.

  • Radcliffe Capital Management reported no remaining Coeptis Therapeutics Warrants position as of Q3 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 70,506 Coeptis Therapeutics Warrants shares in Q3 2023, an estimated $5.25K.
  • Radcliffe Capital Management first reported a position in Coeptis Therapeutics Warrants in Q1 2021 and held it in 10 quarters.
  • Radcliffe Capital Management's Coeptis Therapeutics Warrants position peaked at $763K in Q3 2022.
  • 19 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.